Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Next Previous
Drug Profile

Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Alternative Names: 3G10; ATH3G10; Fully human monoclonal IgG phosphorylcholine antibody - Athera Biotechnologies; IgG phosphorylcholine antibody; PC-mAb; PCmab; Phosphorylcholine monoclonal antibody - Athera

Latest Information Update: 29 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer Athera Biotechnologies
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis; Myocardial infarction
  • No development reported Peripheral arterial disorders
  • Discontinued Coronary artery restenosis

Most Recent Events

  • 19 Apr 2021 Athera Biotechnologies completes a phase II trial in Myocardial infarction in Sweden, Denmark and Netherlands (NCT03991143) (EudraCT2018-003676-12)
  • 25 Feb 2021 Phase-II development is ongoing in Myocardial infarction in Sweden, Denmark, and Netherlands (IV) (EudraCT2018-003676-12) (NCT03991143)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Peripheral-arterial-disorders(In volunteers) in Unknown
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top